The number of shares and votes in Creaspac AB (the "Company") has changed as a result of the share issue carried out in connection with the listing on Nasdaq Stockholm on 23 June 2021. Through the share issue, the number of outstanding shares and votes in the Company have increased by 24,800,000, from 200,000 to 25,000,000 outstanding shares and votes in the Company.

About Creaspac

Creaspac is a Swedish acquisition company, a so-called Special Purpose Acquisition Company (SPAC), established on the initiative of Creades. The purpose of Creaspac is to raise capital through an initial public offering on Nasdaq Stockholm and within 36 months thereafter acquire an unlisted company which, through Creaspac, after review and approval, will be listed on Nasdaq Stockholm Main Market or Nasdaq First North Growth Market.

More information is available on Creaspac's website, www.creaspac.se.

About Creades

Creades is a Swedish listed investment company that was formed at the end of 2011/2012 in connection with Investment AB Öresund being split into two companies. Creades was listed in 2013 on Nasdaq Stockholm's main market and was before that listed on Nasdaq First North since 2012. Creades' portfolio, measured in terms of substance value, consists of approximately 70-75 percent listed holdings and approximately 25-30 percent unlisted holdings. Creades' largest holding is the listed company Avanza, and Creades' unlisted holdings include Apotea, Inet, Instabox, PriceRunner, Röhnisch, StickerApp and Tink. Creades' net asset value as of 31 May 2021 was SEK 10,341 million.

For more information, please contact:

John Hedberg, CEO

+46 (0) 70 629 23 37

john.hedberg@creaspac.se

This information is information that Creaspac AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. This information was submitted for publication, through the agency of the contact person set out above, on 30 June 2021 at 19.00 CET.

https://news.cision.com/creaspac/r/increased-number-of-shares-and-votes-in-creaspac,c3377477

https://mb.cision.com/Main/20606/3377477/1439083.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English